Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177723 · ClinicalTrials.gov registry record
Towards Reducing Resistance and Hematological Toxicity of Linezolid
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 50
- Enrollment target
NCT00177723 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 50 participants.
The verdict
NCT00177723 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
The study will evaluate and improve the performance of pharmaco-statistical models previously developed in the compassionate use program in patients being treated with linezolid under clinical usage conditions. This study will also develop a sensitive and specific tool that may be used to predict patients at risk of hematological toxicity, based on factors including linezolid concentration and duration of therapy and use these models to better understand the determinants of toxicity with linezolid and define better strategies to manage toxicity or reduce its occurrence.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00177723
The ClinicalTrials.gov registry entry for NCT00177723 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00177723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00177723 about?
NCT00177723 is a clinical study titled "Towards Reducing Resistance and Hematological Toxicity of Linezolid". The study will evaluate and improve the performance of pharmaco-statistical models previously developed in the compassionate use program in patients being treated with linezolid under clinical usage conditions. This study will also develop a sensitive and specific tool that may be used to predict pa...
What is the current status of trial NCT00177723?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2005-08. Estimated completion is 2007-02.
Who is sponsoring clinical trial NCT00177723?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.